After Roaring In 2020, Biotech Stocks Now Weighed Down By Merger Scrutiny, FDA Approval Delays And Possible Drug Pricing Legislation

  • 📰 Forbes
  • ⏱ Reading Time:
  • 12 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 53%

Nigeria News News

Nigeria Nigeria Latest News,Nigeria Nigeria Headlines

After roaring in 2020, biotech stocks are now weighed down by merger scrutiny, FDA approval delays and possible drug pricing legislation

Biotech stocks have been dropping in value since early February, likely depressed by some regulatory and drug pricing concerns, but some analysts think the sector will rebound later this year, partly on the back of M&A deals and new product releases.... [+]

David Nierengarten, a biotech and biopharmaceuticals analyst at Wedbush Securities in Los Angeles, toldthat concerns over stalled new drug approvals by the Food and Drug Administration are likely weighing on the biotech sector.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 394. in NG
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Nigeria Nigeria Latest News, Nigeria Nigeria Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

After Roaring In 2020, Biotech Stocks Now Weighed Down By Merger Scrutiny, FDA Approval Delays And Possible Drug Pricing LegislationI have more than 20 yrs experience in writing about financial markets. I am especially interested in history and literature.
Source: Forbes - 🏆 394. / 53 Read more »

After Roaring In 2020, Biotech Stocks Now Weighed Down By Merger Scrutiny, FDA Approval Delays And Possible Drug Pricing LegislationAfter roaring in 2020, biotech stocks are now weighed down by merger scrutiny, FDA approval delays and possible drug pricing legislation
Source: Forbes - 🏆 394. / 53 Read more »